financial news: Arrayit Diagnostics, Inc. Reports Results of Research Study for Ovarian Cancer Diagnostic Test (OvaDx)

Arrayit Diagnostics, Inc. Reports Results of Research Study for Ovarian Cancer Diagnostic Test

" Arrayit Corporation and Arrayit Diagnostics, Inc. ("AD") report significant results from a 257 patient research study on its pre-symptomatic ovarian cancer molecular diagnostic test in development, OvaDx(R). In this study, OvaDx(R) recorded sensitivity of 79.7%, correctly identifying patients known to have cancer, and specificity approaching 100%, correctly identifying the healthy controls, patients known not to have cancer......

Arrayit Corporation Receives Registered Trademark for OvaDx(R) - financial news

"Arrayit's OvaDx(R), the market's first comprehensive diagnostic screening test for ovarian cancer, uses approximately 100 proteomic biomarkers to identify molecular beacons of ovarian cancer that accumulate in the bloodstream as soon as an ovarian tumor begins to develop. OvaDx(R) detects both early and late stage ovarian cancer with high sensitivity and specificity using Arrayit's proprietary microarrays, which are tiny medical devices that screen large numbers of patient samples in a highly miniaturized and automated manner. OvaDx(R) leverages Arrayit's patented manufacturing technology and will be marketed and sold upon FDA approval by the company's subsidiary Arrayit Diagnostics, Inc."

Arrayit Signs on Docro to Help Ovarian Cancer Diagnostic Gain FDA Clearance GenomeWeb

Vermillion's OVA1 became the first protein-based in vitro diagnostic multivariate index assay to receive FDA clearance [See PM 09/17/09] and earlier this month it and Quest Diagnostics began marketing OVA1.

In addition, Correlogic is in discussions with the FDA about its OvaCheck test,

and

Healthlinx, which launched its test called OvPlex in the UK in February, has said that it may launch the test in the US next year, if it receives regulatory approval.

This week, Arrayit said that OvaDx will be the market's first "comprehensive diagnostic for ovarian cancer" and will be targeted to all women over the age of 35.

Arrayit Corporation - FDA / OvaDx - financial news

"Arrayit's OvaDx Pre-Symptomatic Ovarian Cancer Test will be the market's first comprehensive diagnostic screen for ovarian cancer, and will be recommended for all women over the age of 35. OvaDx uses approximately 100 proteomic biomarkers in a microarray format to identify molecular beacons of ovarian cancer that accumulate in the bloodstream as a result of the body's natural immune response to developing ovarian tumors. Arrayit's microarray test, which detects both early and late stage ovarian cancer..."cont'd